The effect of DPP4 inhibitors on oxidative stress in persons with TD2 and chronic kidney disease has been investigated in a randomised clinical trial (n = 45) comparing the effect of treatment with teneligliptin compared to sitagliptin. The gene discussed is DPP4; the disease is chronic kidney disease.